FILTERS
TOPICS
CritiTech’s Purcision™ Technology Nominated for Most Promising Drug Delivery Technology Award
Patented platform specializes in delivering 100% pure drugs directly to the site of disease Lawrence, KS— May 19, 2025 — … Continued
More >Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment
Ian E. Stewart, Phillip G. Durham, Jacob M. Sittenauer, Aranza P. Barreda, Grayson W. Stowell, Carmella Moody, Jeffery B. Mecham, Catherine Simpson, Sharon Daily, Sara E. Maloney, Mark D. Williams, Diana … Continued
More >CritiTech Particle Engineering Solutions and Aeon Respire Announce Collaboration to Develop Novel Inhaled Formulation of Niclosamide
LAWRENCE, KS – January 25, 2022 – CritiTech Particle Engineering Solutions (“CritiTech”) has entered into a strategic collaboration and licensing … Continued
More >AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder Cancer by CritiTech PES Partner NanOlogy
FORT WORTH (September 21, 2021) — NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that initial results from a … Continued
More >CritiTech PES Partner Nanology Presents Additional Data at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy, LLC, a clinical-stage oncology company, announced today that additional data from its Phase 2 dose-rising and … Continued
More >CritiTech PES Partner NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
FT. WORTH, (April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, announced today the first patient has … Continued
More >CritiTech PES partner NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its … Continued
More >CritiTech PES partner NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
FT. WORTH, (December 29, 2020) — NanOlogy, LLC, a clinical-stage oncology company, today announced that results from its Phase 1/2 clinical … Continued
More >CritiTech PES partner NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
Follows completion of a first-in-human dose-rising study of a single focal injection of NanoPac in patients with local prostate cancer … Continued
More >CritiTech PES partner NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
First-in-human clinical trial of intratumoral (IT) injections of NanoPac in non-small cell lung cancer (NSCLC) and small cell lung cancer … Continued
More >